Champions Oncology
NASDAQ: CSBRHackensack, US · Founded 2007 · Delaware corporation · 184 employees on LinkedIn · 3 known investors
Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance. It serves pharma and biotech teams developing KRAS-directed cancer therapies for NSCLC, pancreatic (PDAC), and colorectal cancers, providing benchmarking, biomarker, and combination-strategy evidence.
Founders & leadership
Champions Oncology was founded in 2007 by Ronnie Morris and Ronnie Morris, M.D..
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$16M disclosed across 3 rounds · 2012–2015
▶$14MraisedMar 2015 · 11 investors · BiotechnologyRule 506(b)
- James McGorryExecutive Officer
- David MillerExecutive Officer
- Daniel MendelsonDirector
- Joel AckermanExecutive Officer, Director
- Abba David PoliakoffDirector
- David SidranskyDirector
- Arthur Epker, IIIDirector
- Scott TobinDirector
- Ronnie MorrisExecutive Officer, Director
- Offering amount
- $14M
- Amount sold
- $14M
- Minimum investment
- $1
- Sales commissions
- $640.5K
- Placement agents
- MTS Securities, LLC
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2014 · 2 investors · BiotechnologyRule 506(b)
- Joel AckermanExecutive Officer, Director
- Scott TobinDirector
- Abba David PoliakoffDirector
- Arthur Epker, IIIDirector
- David SidrankskyDirector
- David MillerExecutive Officer
- Ronnie MorrisDirector
- Daniel MendelsonDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $1M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5KraisedFeb 2012 · 1 investors · BiotechnologyRule 506(b)
- Joel AckermanExecutive Officer, Director
- David Sidransky, M.D.Director
- Scott TobinDirector
- Ronnie Morris, M.D.Executive Officer, Director
- Abba D. PoliakoffDirector
- James M. MartellDirector
- Ana I. StancicDirector
- Offering amount
- $8.5K
- Amount sold
- $8.5K
- Minimum investment
- $8.5K
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Companies competing with Champions Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Champions Oncology do?
- Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance. It serves pharma and biotech teams developing KRAS-directed cancer therapies for NSCLC, pancreatic (PDAC), and colorectal cancers, providing benchmarking, biomarker, and combination-strategy evidence.
- Who founded Champions Oncology?
- Champions Oncology was founded by Ronnie Morris, Ronnie Morris, M.D. in 2007.
- Who are Champions Oncology's investors?
- Champions Oncology's investors include Battery Ventures, New Enterprise Associates (NEA), Israel Biotech Fund.
- How much funding has Champions Oncology raised?
- Champions Oncology has disclosed $16M raised across 3 rounds.
- Where is Champions Oncology headquartered?
- Champions Oncology is headquartered in Hackensack, US.